Robert Grosse

Current Position

Full professor and chair, Institute of Experimental and Clinical Pharmacology and Toxicology

Academic Education

1997	Graduation from Medical School, Free University Berlin
1996	Internship at St. Mary’s Hospital, Imperial College, London, UK
1992 - 1993	Research assistant, Georgetown University Medical Center, Washington DC, USA

Advanced Qualifications

2009	Habilitation, Pharmacology and Toxicology, University of Heidelberg,
2006	Medical specialization in Pharmacology and Toxicology, University of Heidelberg
1999	Full medical license (‘Approbation zum Arzt’), Free University Berlin
1999	Doctoral dissertation (summa cum laude), Free University Berlin

Postgraduate Positions

2019 - present	Full professor (W3) and head of department, Institute of Experimental and Clinical Pharmacology, Medical Faculty, University of Freiburg
2009 - 2018	Full professor (W3) and director of the Institute of Pharmacology, Medical Faculty, University of Marburg
2004 - 2009	Principal Investigator (Emmy-Noether-Program), Institute of Pharmacology, University of Heidelberg
2000 - 2003	Post-doc (EMBO long term fellow), Lincoln’s Inn Fields Laboratories, London Research Institute London, UK (Richard Treisman)
1998 - 2000	Physician Scientist, Institute of Pharmacology, Free University Berlin (Günter Schultz)

Link to all publications of Robert Grosse: PubMed

Publications on CRC 1453 funding

Konwar S, Schroda S, Rogg M, …, Grosse R, Schell C, Vidal S, Liu X, Gorzelanny C, Tschongov T, Häffner K. Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Invest (2025). Maas-Bauer, Stell AV, Yan KL, de Vega E, Vinnakota JM, …, Grosse R, …, Becher B, Börries M, Zeiser R. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nat Commun (2024).